nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—Gout—Mesalazine—Crohn's disease	0.00584	0.00698	CcSEcCtD
Nefazodone—Colitis—Azathioprine—Crohn's disease	0.00575	0.00687	CcSEcCtD
Nefazodone—Neck pain—Mesalazine—Crohn's disease	0.00552	0.0066	CcSEcCtD
Nefazodone—Stomatitis—Mercaptopurine—Crohn's disease	0.00548	0.00655	CcSEcCtD
Nefazodone—Vaginal inflammation—Mesalazine—Crohn's disease	0.00545	0.00652	CcSEcCtD
Nefazodone—Abnormal dreams—Mesalazine—Crohn's disease	0.00539	0.00644	CcSEcCtD
Nefazodone—Eructation—Mesalazine—Crohn's disease	0.00536	0.00641	CcSEcCtD
Nefazodone—Cystitis noninfective—Mesalazine—Crohn's disease	0.00533	0.00637	CcSEcCtD
Nefazodone—Cystitis—Mesalazine—Crohn's disease	0.00527	0.0063	CcSEcCtD
Nefazodone—Colitis—Mesalazine—Crohn's disease	0.00524	0.00626	CcSEcCtD
Nefazodone—Candida infection—Mesalazine—Crohn's disease	0.00521	0.00623	CcSEcCtD
Nefazodone—Vaginal infection—Mesalazine—Crohn's disease	0.00515	0.00616	CcSEcCtD
Nefazodone—Dry eye—Mesalazine—Crohn's disease	0.00504	0.00602	CcSEcCtD
Nefazodone—Ecchymosis—Mesalazine—Crohn's disease	0.00493	0.0059	CcSEcCtD
Nefazodone—Bladder pain—Mesalazine—Crohn's disease	0.00493	0.0059	CcSEcCtD
Nefazodone—Mouth ulceration—Mesalazine—Crohn's disease	0.00493	0.0059	CcSEcCtD
Nefazodone—Hepatic failure—Azathioprine—Crohn's disease	0.00484	0.00578	CcSEcCtD
Nefazodone—Hypertonia—Mesalazine—Crohn's disease	0.00478	0.00572	CcSEcCtD
Nefazodone—Ear pain—Mesalazine—Crohn's disease	0.00464	0.00555	CcSEcCtD
Nefazodone—Lymphadenopathy—Mesalazine—Crohn's disease	0.00464	0.00555	CcSEcCtD
Nefazodone—Gastroenteritis—Mesalazine—Crohn's disease	0.00447	0.00534	CcSEcCtD
Nefazodone—Alopecia—Mercaptopurine—Crohn's disease	0.00446	0.00533	CcSEcCtD
Nefazodone—Deafness—Mesalazine—Crohn's disease	0.00443	0.00529	CcSEcCtD
Nefazodone—Eczema—Mesalazine—Crohn's disease	0.00441	0.00527	CcSEcCtD
Nefazodone—Hepatic failure—Mesalazine—Crohn's disease	0.00441	0.00527	CcSEcCtD
Nefazodone—Eye pain—Mesalazine—Crohn's disease	0.00439	0.00524	CcSEcCtD
Nefazodone—Peptic ulcer—Prednisone—Crohn's disease	0.00432	0.00516	CcSEcCtD
Nefazodone—Libido decreased—Mesalazine—Crohn's disease	0.00427	0.0051	CcSEcCtD
Nefazodone—Increased appetite—Mesalazine—Crohn's disease	0.00421	0.00504	CcSEcCtD
Nefazodone—Thirst—Mesalazine—Crohn's disease	0.00416	0.00497	CcSEcCtD
Nefazodone—Dermatitis bullous—Mesalazine—Crohn's disease	0.00414	0.00495	CcSEcCtD
Nefazodone—Suicidal ideation—Prednisone—Crohn's disease	0.00412	0.00492	CcSEcCtD
Nefazodone—Arthritis—Mesalazine—Crohn's disease	0.00407	0.00487	CcSEcCtD
Nefazodone—Anaemia—Mercaptopurine—Crohn's disease	0.00406	0.00485	CcSEcCtD
Nefazodone—Osteoarthritis—Mesalazine—Crohn's disease	0.00396	0.00473	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.00396	0.00473	CcSEcCtD
Nefazodone—Leukopenia—Mercaptopurine—Crohn's disease	0.00393	0.0047	CcSEcCtD
Nefazodone—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.00393	0.0047	CcSEcCtD
Nefazodone—Affect lability—Mesalazine—Crohn's disease	0.0039	0.00466	CcSEcCtD
Nefazodone—Migraine—Mesalazine—Crohn's disease	0.0039	0.00466	CcSEcCtD
Nefazodone—Glaucoma—Prednisone—Crohn's disease	0.00383	0.00458	CcSEcCtD
Nefazodone—Face oedema—Mesalazine—Crohn's disease	0.00382	0.00457	CcSEcCtD
Nefazodone—Mood swings—Mesalazine—Crohn's disease	0.00375	0.00448	CcSEcCtD
Nefazodone—Arthralgia—Mercaptopurine—Crohn's disease	0.00374	0.00447	CcSEcCtD
Nefazodone—Memory impairment—Prednisone—Crohn's disease	0.00368	0.0044	CcSEcCtD
Nefazodone—Liver function test abnormal—Mesalazine—Crohn's disease	0.00366	0.00437	CcSEcCtD
Nefazodone—Dry skin—Mesalazine—Crohn's disease	0.00363	0.00434	CcSEcCtD
Nefazodone—Orthostatic hypotension—Mesalazine—Crohn's disease	0.00362	0.00432	CcSEcCtD
Nefazodone—Oedema—Mercaptopurine—Crohn's disease	0.00359	0.00429	CcSEcCtD
Nefazodone—Cramp muscle—Mesalazine—Crohn's disease	0.00357	0.00426	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00357	0.00426	CcSEcCtD
Nefazodone—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00351	0.0042	CcSEcCtD
Nefazodone—Gastritis—Mesalazine—Crohn's disease	0.0035	0.00419	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00349	0.00417	CcSEcCtD
Nefazodone—Abdominal distension—Mesalazine—Crohn's disease	0.00344	0.00412	CcSEcCtD
Nefazodone—Dysphagia—Mesalazine—Crohn's disease	0.00342	0.00409	CcSEcCtD
Nefazodone—Influenza—Mesalazine—Crohn's disease	0.00342	0.00409	CcSEcCtD
Nefazodone—Asthma—Mesalazine—Crohn's disease	0.00342	0.00409	CcSEcCtD
Nefazodone—Anorexia—Mercaptopurine—Crohn's disease	0.00342	0.00409	CcSEcCtD
Nefazodone—Pneumonia—Azathioprine—Crohn's disease	0.00337	0.00403	CcSEcCtD
Nefazodone—Angina pectoris—Mesalazine—Crohn's disease	0.00333	0.00398	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00332	0.00397	CcSEcCtD
Nefazodone—Bronchitis—Mesalazine—Crohn's disease	0.00329	0.00393	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00327	0.00391	CcSEcCtD
Nefazodone—Dysuria—Mesalazine—Crohn's disease	0.0032	0.00383	CcSEcCtD
Nefazodone—Pollakiuria—Mesalazine—Crohn's disease	0.00316	0.00378	CcSEcCtD
Nefazodone—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00312	0.00373	CcSEcCtD
Nefazodone—Decreased appetite—Mercaptopurine—Crohn's disease	0.00312	0.00373	CcSEcCtD
Nefazodone—Weight increased—Mesalazine—Crohn's disease	0.00311	0.00372	CcSEcCtD
Nefazodone—Weight decreased—Mesalazine—Crohn's disease	0.0031	0.0037	CcSEcCtD
Nefazodone—Pneumonia—Mesalazine—Crohn's disease	0.00307	0.00367	CcSEcCtD
Nefazodone—Hypercholesterolaemia—Prednisone—Crohn's disease	0.00305	0.00365	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00302	0.00362	CcSEcCtD
Nefazodone—Haemoglobin—Azathioprine—Crohn's disease	0.00302	0.00361	CcSEcCtD
Nefazodone—Haemorrhage—Azathioprine—Crohn's disease	0.00301	0.00359	CcSEcCtD
Nefazodone—Stomatitis—Mesalazine—Crohn's disease	0.00297	0.00356	CcSEcCtD
Nefazodone—Conjunctivitis—Mesalazine—Crohn's disease	0.00297	0.00355	CcSEcCtD
Nefazodone—Urinary tract infection—Mesalazine—Crohn's disease	0.00297	0.00355	CcSEcCtD
Nefazodone—Sweating—Mesalazine—Crohn's disease	0.00293	0.0035	CcSEcCtD
Nefazodone—Haematuria—Mesalazine—Crohn's disease	0.00291	0.00348	CcSEcCtD
Nefazodone—Hiccups—Prednisone—Crohn's disease	0.00289	0.00345	CcSEcCtD
Nefazodone—Epistaxis—Mesalazine—Crohn's disease	0.00288	0.00344	CcSEcCtD
Nefazodone—Sinusitis—Mesalazine—Crohn's disease	0.00286	0.00342	CcSEcCtD
Nefazodone—Erythema multiforme—Azathioprine—Crohn's disease	0.00284	0.0034	CcSEcCtD
Nefazodone—Body temperature increased—Mercaptopurine—Crohn's disease	0.00283	0.00339	CcSEcCtD
Nefazodone—Haemoglobin—Mesalazine—Crohn's disease	0.00275	0.00329	CcSEcCtD
Nefazodone—Rhinitis—Mesalazine—Crohn's disease	0.00275	0.00328	CcSEcCtD
Nefazodone—Hepatitis—Mesalazine—Crohn's disease	0.00274	0.00327	CcSEcCtD
Nefazodone—Haemorrhage—Mesalazine—Crohn's disease	0.00274	0.00327	CcSEcCtD
Nefazodone—Pharyngitis—Mesalazine—Crohn's disease	0.00272	0.00325	CcSEcCtD
Nefazodone—Oedema peripheral—Mesalazine—Crohn's disease	0.0027	0.00323	CcSEcCtD
Nefazodone—Chills—Azathioprine—Crohn's disease	0.0027	0.00323	CcSEcCtD
Nefazodone—Alopecia—Azathioprine—Crohn's disease	0.00266	0.00318	CcSEcCtD
Nefazodone—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00264	0.00316	CcSEcCtD
Nefazodone—Oesophagitis—Prednisone—Crohn's disease	0.00264	0.00315	CcSEcCtD
Nefazodone—Ecchymosis—Prednisone—Crohn's disease	0.00261	0.00312	CcSEcCtD
Nefazodone—Erythema multiforme—Mesalazine—Crohn's disease	0.00259	0.0031	CcSEcCtD
Nefazodone—Tinnitus—Mesalazine—Crohn's disease	0.00255	0.00305	CcSEcCtD
Nefazodone—Hyperkinesia—Prednisone—Crohn's disease	0.00252	0.00301	CcSEcCtD
Nefazodone—Euphoric mood—Prednisone—Crohn's disease	0.00248	0.00296	CcSEcCtD
Nefazodone—Chills—Mesalazine—Crohn's disease	0.00246	0.00294	CcSEcCtD
Nefazodone—Diarrhoea—Mercaptopurine—Crohn's disease	0.00245	0.00293	CcSEcCtD
Nefazodone—Ill-defined disorder—Azathioprine—Crohn's disease	0.00243	0.0029	CcSEcCtD
Nefazodone—Alopecia—Mesalazine—Crohn's disease	0.00242	0.00289	CcSEcCtD
Nefazodone—Anaemia—Azathioprine—Crohn's disease	0.00242	0.00289	CcSEcCtD
Nefazodone—Malaise—Azathioprine—Crohn's disease	0.00236	0.00282	CcSEcCtD
Nefazodone—Flatulence—Mesalazine—Crohn's disease	0.00235	0.00281	CcSEcCtD
Nefazodone—Leukopenia—Azathioprine—Crohn's disease	0.00234	0.0028	CcSEcCtD
Nefazodone—Dysgeusia—Mesalazine—Crohn's disease	0.00233	0.00279	CcSEcCtD
Nefazodone—Cardiac failure congestive—Prednisone—Crohn's disease	0.00231	0.00276	CcSEcCtD
Nefazodone—Back pain—Mesalazine—Crohn's disease	0.00231	0.00276	CcSEcCtD
Nefazodone—Muscle spasms—Mesalazine—Crohn's disease	0.00229	0.00274	CcSEcCtD
Nefazodone—Vomiting—Mercaptopurine—Crohn's disease	0.00228	0.00273	CcSEcCtD
Nefazodone—Injury—Prednisone—Crohn's disease	0.00228	0.00272	CcSEcCtD
Nefazodone—Rash—Mercaptopurine—Crohn's disease	0.00226	0.0027	CcSEcCtD
Nefazodone—Dermatitis—Mercaptopurine—Crohn's disease	0.00226	0.0027	CcSEcCtD
Nefazodone—Vision blurred—Mesalazine—Crohn's disease	0.00225	0.00269	CcSEcCtD
Nefazodone—Tremor—Mesalazine—Crohn's disease	0.00223	0.00267	CcSEcCtD
Nefazodone—Increased appetite—Prednisone—Crohn's disease	0.00223	0.00267	CcSEcCtD
Nefazodone—Myalgia—Azathioprine—Crohn's disease	0.00223	0.00266	CcSEcCtD
Nefazodone—Arthralgia—Azathioprine—Crohn's disease	0.00223	0.00266	CcSEcCtD
Nefazodone—Ill-defined disorder—Mesalazine—Crohn's disease	0.00221	0.00264	CcSEcCtD
Nefazodone—Anaemia—Mesalazine—Crohn's disease	0.0022	0.00263	CcSEcCtD
Nefazodone—Discomfort—Azathioprine—Crohn's disease	0.0022	0.00263	CcSEcCtD
Nefazodone—Angioedema—Mesalazine—Crohn's disease	0.00218	0.0026	CcSEcCtD
Nefazodone—Malaise—Mesalazine—Crohn's disease	0.00215	0.00257	CcSEcCtD
Nefazodone—Vertigo—Mesalazine—Crohn's disease	0.00214	0.00256	CcSEcCtD
Nefazodone—Syncope—Mesalazine—Crohn's disease	0.00214	0.00256	CcSEcCtD
Nefazodone—Leukopenia—Mesalazine—Crohn's disease	0.00213	0.00255	CcSEcCtD
Nefazodone—Nausea—Mercaptopurine—Crohn's disease	0.00213	0.00255	CcSEcCtD
Nefazodone—Infection—Azathioprine—Crohn's disease	0.00212	0.00254	CcSEcCtD
Nefazodone—Palpitations—Mesalazine—Crohn's disease	0.00211	0.00252	CcSEcCtD
Nefazodone—Loss of consciousness—Mesalazine—Crohn's disease	0.0021	0.00251	CcSEcCtD
Nefazodone—Osteoarthritis—Prednisone—Crohn's disease	0.00209	0.0025	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.00209	0.0025	CcSEcCtD
Nefazodone—Thrombocytopenia—Azathioprine—Crohn's disease	0.00209	0.0025	CcSEcCtD
Nefazodone—Cough—Mesalazine—Crohn's disease	0.00208	0.00249	CcSEcCtD
Nefazodone—Affect lability—Prednisone—Crohn's disease	0.00206	0.00246	CcSEcCtD
Nefazodone—Hypertension—Mesalazine—Crohn's disease	0.00206	0.00246	CcSEcCtD
Nefazodone—Chest pain—Mesalazine—Crohn's disease	0.00203	0.00243	CcSEcCtD
Nefazodone—Myalgia—Mesalazine—Crohn's disease	0.00203	0.00243	CcSEcCtD
Nefazodone—Arthralgia—Mesalazine—Crohn's disease	0.00203	0.00243	CcSEcCtD
Nefazodone—Anxiety—Mesalazine—Crohn's disease	0.00202	0.00242	CcSEcCtD
Nefazodone—Face oedema—Prednisone—Crohn's disease	0.00202	0.00242	CcSEcCtD
Nefazodone—Discomfort—Mesalazine—Crohn's disease	0.00201	0.0024	CcSEcCtD
Nefazodone—Hypotension—Azathioprine—Crohn's disease	0.002	0.00239	CcSEcCtD
Nefazodone—Dry mouth—Mesalazine—Crohn's disease	0.00199	0.00237	CcSEcCtD
Nefazodone—Mood swings—Prednisone—Crohn's disease	0.00198	0.00237	CcSEcCtD
Nefazodone—Confusional state—Mesalazine—Crohn's disease	0.00196	0.00235	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00195	0.00233	CcSEcCtD
Nefazodone—Anaphylactic shock—Mesalazine—Crohn's disease	0.00195	0.00233	CcSEcCtD
Nefazodone—Oedema—Mesalazine—Crohn's disease	0.00195	0.00233	CcSEcCtD
Nefazodone—Infection—Mesalazine—Crohn's disease	0.00193	0.00231	CcSEcCtD
Nefazodone—Dry skin—Prednisone—Crohn's disease	0.00192	0.0023	CcSEcCtD
Nefazodone—Shock—Mesalazine—Crohn's disease	0.00191	0.00229	CcSEcCtD
Nefazodone—Thrombocytopenia—Mesalazine—Crohn's disease	0.00191	0.00228	CcSEcCtD
Nefazodone—Tachycardia—Mesalazine—Crohn's disease	0.0019	0.00227	CcSEcCtD
Nefazodone—Hyperhidrosis—Mesalazine—Crohn's disease	0.00188	0.00225	CcSEcCtD
Nefazodone—Anorexia—Mesalazine—Crohn's disease	0.00185	0.00222	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.00185	0.00221	CcSEcCtD
Nefazodone—Abdominal distension—Prednisone—Crohn's disease	0.00182	0.00218	CcSEcCtD
Nefazodone—Hypotension—Mesalazine—Crohn's disease	0.00182	0.00217	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00177	0.00212	CcSEcCtD
Nefazodone—Feeling abnormal—Azathioprine—Crohn's disease	0.00176	0.0021	CcSEcCtD
Nefazodone—Insomnia—Mesalazine—Crohn's disease	0.00176	0.0021	CcSEcCtD
Nefazodone—Paraesthesia—Mesalazine—Crohn's disease	0.00175	0.00209	CcSEcCtD
Nefazodone—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00175	0.00209	CcSEcCtD
Nefazodone—Dyspnoea—Mesalazine—Crohn's disease	0.00173	0.00207	CcSEcCtD
Nefazodone—Somnolence—Mesalazine—Crohn's disease	0.00173	0.00207	CcSEcCtD
Nefazodone—Dyspepsia—Mesalazine—Crohn's disease	0.00171	0.00205	CcSEcCtD
Nefazodone—Decreased appetite—Mesalazine—Crohn's disease	0.00169	0.00202	CcSEcCtD
Nefazodone—Abdominal pain—Azathioprine—Crohn's disease	0.00169	0.00202	CcSEcCtD
Nefazodone—Body temperature increased—Azathioprine—Crohn's disease	0.00169	0.00202	CcSEcCtD
Nefazodone—Erectile dysfunction—Prednisone—Crohn's disease	0.00167	0.00199	CcSEcCtD
Nefazodone—Pain—Mesalazine—Crohn's disease	0.00166	0.00199	CcSEcCtD
Nefazodone—Constipation—Mesalazine—Crohn's disease	0.00166	0.00199	CcSEcCtD
Nefazodone—Weight increased—Prednisone—Crohn's disease	0.00165	0.00197	CcSEcCtD
Nefazodone—Weight decreased—Prednisone—Crohn's disease	0.00164	0.00196	CcSEcCtD
Nefazodone—Feeling abnormal—Mesalazine—Crohn's disease	0.0016	0.00192	CcSEcCtD
Nefazodone—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00159	0.0019	CcSEcCtD
Nefazodone—Hypersensitivity—Azathioprine—Crohn's disease	0.00157	0.00188	CcSEcCtD
Nefazodone—Urticaria—Mesalazine—Crohn's disease	0.00155	0.00185	CcSEcCtD
Nefazodone—Abdominal pain—Mesalazine—Crohn's disease	0.00154	0.00184	CcSEcCtD
Nefazodone—Body temperature increased—Mesalazine—Crohn's disease	0.00154	0.00184	CcSEcCtD
Nefazodone—Bradycardia—Prednisone—Crohn's disease	0.00148	0.00176	CcSEcCtD
Nefazodone—Diarrhoea—Azathioprine—Crohn's disease	0.00146	0.00175	CcSEcCtD
Nefazodone—Haemoglobin—Prednisone—Crohn's disease	0.00146	0.00174	CcSEcCtD
Nefazodone—Haemorrhage—Prednisone—Crohn's disease	0.00145	0.00173	CcSEcCtD
Nefazodone—Hallucination—Prednisone—Crohn's disease	0.00144	0.00172	CcSEcCtD
Nefazodone—Hypersensitivity—Mesalazine—Crohn's disease	0.00143	0.00171	CcSEcCtD
Nefazodone—Dizziness—Azathioprine—Crohn's disease	0.00141	0.00169	CcSEcCtD
Nefazodone—Asthenia—Mesalazine—Crohn's disease	0.0014	0.00167	CcSEcCtD
Nefazodone—Pruritus—Mesalazine—Crohn's disease	0.00138	0.00165	CcSEcCtD
Nefazodone—Vomiting—Azathioprine—Crohn's disease	0.00136	0.00162	CcSEcCtD
Nefazodone—Rash—Azathioprine—Crohn's disease	0.00135	0.00161	CcSEcCtD
Nefazodone—Dermatitis—Azathioprine—Crohn's disease	0.00135	0.00161	CcSEcCtD
Nefazodone—Flushing—Prednisone—Crohn's disease	0.00134	0.00161	CcSEcCtD
Nefazodone—Headache—Azathioprine—Crohn's disease	0.00134	0.0016	CcSEcCtD
Nefazodone—Diarrhoea—Mesalazine—Crohn's disease	0.00133	0.00159	CcSEcCtD
Nefazodone—Dizziness—Mesalazine—Crohn's disease	0.00129	0.00154	CcSEcCtD
Nefazodone—Alopecia—Prednisone—Crohn's disease	0.00128	0.00153	CcSEcCtD
Nefazodone—Nausea—Azathioprine—Crohn's disease	0.00127	0.00152	CcSEcCtD
Nefazodone—Vomiting—Mesalazine—Crohn's disease	0.00124	0.00148	CcSEcCtD
Nefazodone—Rash—Mesalazine—Crohn's disease	0.00123	0.00147	CcSEcCtD
Nefazodone—Dermatitis—Mesalazine—Crohn's disease	0.00123	0.00147	CcSEcCtD
Nefazodone—Headache—Mesalazine—Crohn's disease	0.00122	0.00146	CcSEcCtD
Nefazodone—Vision blurred—Prednisone—Crohn's disease	0.00119	0.00142	CcSEcCtD
Nefazodone—Ill-defined disorder—Prednisone—Crohn's disease	0.00117	0.0014	CcSEcCtD
Nefazodone—Anaemia—Prednisone—Crohn's disease	0.00117	0.00139	CcSEcCtD
Nefazodone—Agitation—Prednisone—Crohn's disease	0.00116	0.00139	CcSEcCtD
Nefazodone—Nausea—Mesalazine—Crohn's disease	0.00116	0.00138	CcSEcCtD
Nefazodone—Angioedema—Prednisone—Crohn's disease	0.00115	0.00138	CcSEcCtD
Nefazodone—Malaise—Prednisone—Crohn's disease	0.00114	0.00136	CcSEcCtD
Nefazodone—Vertigo—Prednisone—Crohn's disease	0.00113	0.00135	CcSEcCtD
Nefazodone—Syncope—Prednisone—Crohn's disease	0.00113	0.00135	CcSEcCtD
Nefazodone—Loss of consciousness—Prednisone—Crohn's disease	0.00111	0.00133	CcSEcCtD
Nefazodone—Convulsion—Prednisone—Crohn's disease	0.00109	0.00131	CcSEcCtD
Nefazodone—Hypertension—Prednisone—Crohn's disease	0.00109	0.0013	CcSEcCtD
Nefazodone—Arthralgia—Prednisone—Crohn's disease	0.00107	0.00128	CcSEcCtD
Nefazodone—Myalgia—Prednisone—Crohn's disease	0.00107	0.00128	CcSEcCtD
Nefazodone—Anxiety—Prednisone—Crohn's disease	0.00107	0.00128	CcSEcCtD
Nefazodone—Discomfort—Prednisone—Crohn's disease	0.00106	0.00127	CcSEcCtD
Nefazodone—Oedema—Prednisone—Crohn's disease	0.00103	0.00123	CcSEcCtD
Nefazodone—Anaphylactic shock—Prednisone—Crohn's disease	0.00103	0.00123	CcSEcCtD
Nefazodone—Infection—Prednisone—Crohn's disease	0.00102	0.00122	CcSEcCtD
Nefazodone—Shock—Prednisone—Crohn's disease	0.00101	0.00121	CcSEcCtD
Nefazodone—Tachycardia—Prednisone—Crohn's disease	0.001	0.0012	CcSEcCtD
Nefazodone—Hyperhidrosis—Prednisone—Crohn's disease	0.000995	0.00119	CcSEcCtD
Nefazodone—Anorexia—Prednisone—Crohn's disease	0.000981	0.00117	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000938	0.00112	CcSEcCtD
Nefazodone—Insomnia—Prednisone—Crohn's disease	0.000931	0.00111	CcSEcCtD
Nefazodone—Paraesthesia—Prednisone—Crohn's disease	0.000925	0.00111	CcSEcCtD
Nefazodone—Dyspepsia—Prednisone—Crohn's disease	0.000906	0.00108	CcSEcCtD
Nefazodone—Decreased appetite—Prednisone—Crohn's disease	0.000895	0.00107	CcSEcCtD
Nefazodone—Constipation—Prednisone—Crohn's disease	0.00088	0.00105	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisone—Crohn's disease	0.000848	0.00101	CcSEcCtD
Nefazodone—Gastrointestinal pain—Prednisone—Crohn's disease	0.000842	0.00101	CcSEcCtD
Nefazodone—Urticaria—Prednisone—Crohn's disease	0.000818	0.000978	CcSEcCtD
Nefazodone—Abdominal pain—Prednisone—Crohn's disease	0.000814	0.000973	CcSEcCtD
Nefazodone—Body temperature increased—Prednisone—Crohn's disease	0.000814	0.000973	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisone—Crohn's disease	0.000759	0.000907	CcSEcCtD
Nefazodone—Asthenia—Prednisone—Crohn's disease	0.000739	0.000883	CcSEcCtD
Nefazodone—Pruritus—Prednisone—Crohn's disease	0.000728	0.000871	CcSEcCtD
Nefazodone—Diarrhoea—Prednisone—Crohn's disease	0.000704	0.000842	CcSEcCtD
Nefazodone—Dizziness—Prednisone—Crohn's disease	0.000681	0.000814	CcSEcCtD
Nefazodone—Vomiting—Prednisone—Crohn's disease	0.000655	0.000783	CcSEcCtD
Nefazodone—Rash—Prednisone—Crohn's disease	0.000649	0.000776	CcSEcCtD
Nefazodone—Dermatitis—Prednisone—Crohn's disease	0.000649	0.000775	CcSEcCtD
Nefazodone—Headache—Prednisone—Crohn's disease	0.000645	0.000771	CcSEcCtD
Nefazodone—Nausea—Prednisone—Crohn's disease	0.000612	0.000731	CcSEcCtD
Nefazodone—ADRA2A—GPCR downstream signaling—CCR6—Crohn's disease	0.000121	0.00074	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000121	0.000739	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CCR6—Crohn's disease	0.000121	0.000739	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MTMR3—Crohn's disease	0.00012	0.000737	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCR9—Crohn's disease	0.000119	0.000726	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CCR6—Crohn's disease	0.000118	0.000723	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SEL1L—Crohn's disease	0.000118	0.00072	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GCKR—Crohn's disease	0.000117	0.000718	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PTGER4—Crohn's disease	0.000117	0.000717	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000117	0.000716	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GPR65—Crohn's disease	0.000116	0.000709	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—IL3—Crohn's disease	0.000115	0.000706	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SEL1L—Crohn's disease	0.000115	0.000705	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GPR65—Crohn's disease	0.000115	0.000705	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000115	0.000705	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—IL3—Crohn's disease	0.000115	0.000702	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000115	0.000701	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000115	0.000701	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000114	0.000697	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—IL6—Crohn's disease	0.000113	0.000691	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RSPO3—Crohn's disease	0.000113	0.000691	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000112	0.000683	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000111	0.000679	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GPR65—Crohn's disease	0.00011	0.000675	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—IL3—Crohn's disease	0.00011	0.000672	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CCR6—Crohn's disease	0.00011	0.000672	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.00011	0.000671	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCR9—Crohn's disease	0.000108	0.000659	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SEL1L—Crohn's disease	0.000107	0.000655	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PLA2G4F—Crohn's disease	0.000107	0.000654	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000107	0.000651	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000106	0.00065	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PTGER4—Crohn's disease	0.000106	0.00065	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCR9—Crohn's disease	0.000105	0.000645	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL3—Crohn's disease	0.000105	0.000641	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL3—Crohn's disease	0.000104	0.000638	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PTGER4—Crohn's disease	0.000104	0.000637	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—FADS1—Crohn's disease	0.000102	0.000626	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—RASGRP1—Crohn's disease	0.000101	0.00062	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—RASGRP1—Crohn's disease	0.000101	0.000617	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	0.000101	0.000616	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—IL2RA—Crohn's disease	0.000101	0.000615	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GPR65—Crohn's disease	0.0001	0.000612	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL3—Crohn's disease	9.98e-05	0.000611	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—IL3—Crohn's disease	9.97e-05	0.00061	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	9.96e-05	0.000609	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—ALB—Crohn's disease	9.88e-05	0.000604	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GPR65—Crohn's disease	9.8e-05	0.0006	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCR9—Crohn's disease	9.8e-05	0.000599	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—IL3—Crohn's disease	9.76e-05	0.000597	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—IL6—Crohn's disease	9.76e-05	0.000597	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	9.75e-05	0.000596	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PTGER4—Crohn's disease	9.67e-05	0.000592	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—RASGRP1—Crohn's disease	9.65e-05	0.000591	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—RASGRP1—Crohn's disease	9.64e-05	0.00059	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GPX4—Crohn's disease	9.59e-05	0.000587	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	9.59e-05	0.000587	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—RASGRP1—Crohn's disease	9.44e-05	0.000578	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—FADS1—Crohn's disease	9.39e-05	0.000574	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GCKR—Crohn's disease	9.26e-05	0.000567	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GPR65—Crohn's disease	9.11e-05	0.000557	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTMR3—Crohn's disease	9.09e-05	0.000556	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—IL3—Crohn's disease	9.07e-05	0.000555	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	9.06e-05	0.000554	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL3—Crohn's disease	9.06e-05	0.000554	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL3—Crohn's disease	8.87e-05	0.000542	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GPX4—Crohn's disease	8.79e-05	0.000538	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—CXCL8—Crohn's disease	8.78e-05	0.000537	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—RASGRP1—Crohn's disease	8.77e-05	0.000537	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—RASGRP1—Crohn's disease	8.76e-05	0.000536	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—ALB—Crohn's disease	8.76e-05	0.000535	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—CXCL8—Crohn's disease	8.73e-05	0.000534	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	8.7e-05	0.000532	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—RASGRP1—Crohn's disease	8.58e-05	0.000525	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTMR3—Crohn's disease	8.57e-05	0.000524	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GCKR—Crohn's disease	8.49e-05	0.000519	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—CXCL8—Crohn's disease	8.36e-05	0.000511	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	8.33e-05	0.000509	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCR6—Crohn's disease	8.26e-05	0.000505	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL3—Crohn's disease	8.24e-05	0.000504	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCR6—Crohn's disease	8.21e-05	0.000502	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—IL2RA—Crohn's disease	8.09e-05	0.000495	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—IL2RA—Crohn's disease	8.04e-05	0.000492	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—RASGRP1—Crohn's disease	7.97e-05	0.000487	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCR6—Crohn's disease	7.86e-05	0.000481	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—IL2RA—Crohn's disease	7.7e-05	0.000471	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—CXCL8—Crohn's disease	7.58e-05	0.000464	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	7.55e-05	0.000462	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RBX1—Crohn's disease	7.47e-05	0.000457	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RBX1—Crohn's disease	7.43e-05	0.000454	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—CXCL8—Crohn's disease	7.42e-05	0.000454	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	7.4e-05	0.000452	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL2RA—Crohn's disease	7.34e-05	0.000449	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL2RA—Crohn's disease	7.31e-05	0.000447	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—ALB—Crohn's disease	7.27e-05	0.000445	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTGER4—Crohn's disease	7.27e-05	0.000445	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTGER4—Crohn's disease	7.23e-05	0.000442	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCR6—Crohn's disease	7.13e-05	0.000436	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RBX1—Crohn's disease	7.11e-05	0.000435	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—FADS1—Crohn's disease	7.08e-05	0.000433	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL2RA—Crohn's disease	6.99e-05	0.000428	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—IL2RA—Crohn's disease	6.99e-05	0.000427	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCR6—Crohn's disease	6.99e-05	0.000427	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTGER4—Crohn's disease	6.92e-05	0.000423	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—CXCL8—Crohn's disease	6.9e-05	0.000422	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—IL2RA—Crohn's disease	6.84e-05	0.000418	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—JAK2—Crohn's disease	6.76e-05	0.000413	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—FADS1—Crohn's disease	6.67e-05	0.000408	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX4—Crohn's disease	6.63e-05	0.000406	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	6.59e-05	0.000403	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—UBE2D1—Crohn's disease	6.55e-05	0.000401	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—UBE2D1—Crohn's disease	6.51e-05	0.000398	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCR6—Crohn's disease	6.49e-05	0.000397	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	6.47e-05	0.000396	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RBX1—Crohn's disease	6.45e-05	0.000395	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GCKR—Crohn's disease	6.4e-05	0.000392	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—IL2RA—Crohn's disease	6.36e-05	0.000389	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RIPK2—Crohn's disease	6.35e-05	0.000388	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL2RA—Crohn's disease	6.34e-05	0.000388	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RIPK2—Crohn's disease	6.32e-05	0.000386	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RBX1—Crohn's disease	6.32e-05	0.000386	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTGER4—Crohn's disease	6.28e-05	0.000384	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX4—Crohn's disease	6.25e-05	0.000382	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—UBE2D1—Crohn's disease	6.24e-05	0.000381	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL2RA—Crohn's disease	6.21e-05	0.00038	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL3—Crohn's disease	6.19e-05	0.000379	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL3—Crohn's disease	6.16e-05	0.000377	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTGER4—Crohn's disease	6.15e-05	0.000376	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RIPK2—Crohn's disease	6.05e-05	0.00037	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GCKR—Crohn's disease	6.04e-05	0.000369	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RASGRP1—Crohn's disease	5.99e-05	0.000366	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RASGRP1—Crohn's disease	5.96e-05	0.000364	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL3—Crohn's disease	5.9e-05	0.000361	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RBX1—Crohn's disease	5.87e-05	0.000359	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL2RA—Crohn's disease	5.77e-05	0.000353	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTGER4—Crohn's disease	5.71e-05	0.000349	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RASGRP1—Crohn's disease	5.7e-05	0.000349	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—UBE2D1—Crohn's disease	5.66e-05	0.000346	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTMR3—Crohn's disease	5.6e-05	0.000343	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—UBE2D1—Crohn's disease	5.54e-05	0.000339	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RIPK2—Crohn's disease	5.49e-05	0.000336	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—JAK2—Crohn's disease	5.43e-05	0.000332	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SOCS1—Crohn's disease	5.43e-05	0.000332	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—JAK2—Crohn's disease	5.41e-05	0.000331	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SOCS1—Crohn's disease	5.4e-05	0.00033	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RIPK2—Crohn's disease	5.37e-05	0.000329	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL3—Crohn's disease	5.35e-05	0.000327	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL3—Crohn's disease	5.24e-05	0.00032	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—JAK2—Crohn's disease	5.18e-05	0.000317	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RASGRP1—Crohn's disease	5.17e-05	0.000316	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—TYK2—Crohn's disease	5.17e-05	0.000316	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SOCS1—Crohn's disease	5.17e-05	0.000316	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—TYK2—Crohn's disease	5.15e-05	0.000315	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—UBE2D1—Crohn's disease	5.15e-05	0.000315	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RASGRP1—Crohn's disease	5.07e-05	0.00031	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RIPK2—Crohn's disease	4.99e-05	0.000305	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CXCL8—Crohn's disease	4.96e-05	0.000303	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—JAK2—Crohn's disease	4.94e-05	0.000302	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CXCL8—Crohn's disease	4.93e-05	0.000302	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TYK2—Crohn's disease	4.93e-05	0.000301	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—JAK2—Crohn's disease	4.91e-05	0.0003	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL3—Crohn's disease	4.87e-05	0.000298	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CXCL8—Crohn's disease	4.72e-05	0.000289	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RASGRP1—Crohn's disease	4.71e-05	0.000288	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—JAK2—Crohn's disease	4.7e-05	0.000287	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—JAK2—Crohn's disease	4.7e-05	0.000287	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SOCS1—Crohn's disease	4.69e-05	0.000287	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SMAD3—Crohn's disease	4.68e-05	0.000287	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SMAD3—Crohn's disease	4.66e-05	0.000285	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—JAK2—Crohn's disease	4.6e-05	0.000281	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SOCS1—Crohn's disease	4.59e-05	0.000281	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CXCL8—Crohn's disease	4.5e-05	0.000276	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CXCL8—Crohn's disease	4.48e-05	0.000274	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TYK2—Crohn's disease	4.47e-05	0.000273	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SMAD3—Crohn's disease	4.46e-05	0.000273	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TYK2—Crohn's disease	4.38e-05	0.000268	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—FADS1—Crohn's disease	4.36e-05	0.000267	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	4.35e-05	0.000266	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2RA—Crohn's disease	4.34e-05	0.000265	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2RA—Crohn's disease	4.32e-05	0.000264	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CXCL8—Crohn's disease	4.29e-05	0.000262	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CXCL8—Crohn's disease	4.29e-05	0.000262	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—JAK2—Crohn's disease	4.27e-05	0.000261	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SOCS1—Crohn's disease	4.26e-05	0.000261	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—JAK2—Crohn's disease	4.26e-05	0.000261	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CXCL8—Crohn's disease	4.2e-05	0.000257	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—JAK2—Crohn's disease	4.17e-05	0.000255	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2RA—Crohn's disease	4.13e-05	0.000253	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX4—Crohn's disease	4.09e-05	0.00025	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TYK2—Crohn's disease	4.07e-05	0.000249	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SMAD3—Crohn's disease	4.05e-05	0.000248	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SMAD3—Crohn's disease	3.96e-05	0.000242	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GCKR—Crohn's disease	3.95e-05	0.000241	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CXCL8—Crohn's disease	3.9e-05	0.000238	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CXCL8—Crohn's disease	3.89e-05	0.000238	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—JAK2—Crohn's disease	3.88e-05	0.000237	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CXCL8—Crohn's disease	3.81e-05	0.000233	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2RA—Crohn's disease	3.75e-05	0.000229	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ALB—Crohn's disease	3.74e-05	0.000229	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SMAD3—Crohn's disease	3.68e-05	0.000225	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2RA—Crohn's disease	3.67e-05	0.000224	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CXCL8—Crohn's disease	3.54e-05	0.000217	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2RA—Crohn's disease	3.41e-05	0.000209	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—Crohn's disease	3.27e-05	0.0002	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TYK2—Crohn's disease	3.06e-05	0.000187	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TYK2—Crohn's disease	3.04e-05	0.000186	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ALB—Crohn's disease	2.95e-05	0.00018	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JAK2—Crohn's disease	2.92e-05	0.000178	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TYK2—Crohn's disease	2.91e-05	0.000178	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JAK2—Crohn's disease	2.9e-05	0.000177	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JAK2—Crohn's disease	2.78e-05	0.00017	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—Crohn's disease	2.7e-05	0.000165	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—Crohn's disease	2.66e-05	0.000163	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—Crohn's disease	2.65e-05	0.000162	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TYK2—Crohn's disease	2.64e-05	0.000161	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TYK2—Crohn's disease	2.59e-05	0.000158	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—Crohn's disease	2.58e-05	0.000158	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—Crohn's disease	2.53e-05	0.000155	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—Crohn's disease	2.53e-05	0.000155	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JAK2—Crohn's disease	2.52e-05	0.000154	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—Crohn's disease	2.52e-05	0.000154	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JAK2—Crohn's disease	2.47e-05	0.000151	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—Crohn's disease	2.41e-05	0.000147	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TYK2—Crohn's disease	2.4e-05	0.000147	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—Crohn's disease	2.36e-05	0.000145	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—Crohn's disease	2.3e-05	0.000141	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JAK2—Crohn's disease	2.29e-05	0.00014	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—Crohn's disease	2.25e-05	0.000138	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—Crohn's disease	2.19e-05	0.000134	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—Crohn's disease	2.14e-05	0.000131	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—Crohn's disease	2.14e-05	0.000131	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—Crohn's disease	2.13e-05	0.00013	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—Crohn's disease	2.09e-05	0.000128	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—Crohn's disease	2.04e-05	0.000125	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—Crohn's disease	2.04e-05	0.000125	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—Crohn's disease	1.99e-05	0.000122	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—Crohn's disease	1.92e-05	0.000117	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—Crohn's disease	1.85e-05	0.000113	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—Crohn's disease	1.81e-05	0.000111	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—Crohn's disease	1.78e-05	0.000109	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—Crohn's disease	1.68e-05	0.000103	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—Crohn's disease	1.68e-05	0.000103	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—Crohn's disease	1.49e-05	9.14e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—Crohn's disease	1.49e-05	9.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—Crohn's disease	1.42e-05	8.71e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—Crohn's disease	1.29e-05	7.9e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—Crohn's disease	1.26e-05	7.73e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—Crohn's disease	1.26e-05	7.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—Crohn's disease	1.17e-05	7.19e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.1e-05	6.72e-05	CbGpPWpGaD
